Research and Development, Nonclinical Studies and First-In-Human and Phase Ⅰ/Ⅱ Clinical Trials of Conditionally Replicating Adenovirus Targeting and Treating with Multiple Factors (m-CRA) for Next-Generation Oncolytic Virus Immunotherapy.